Sartorius Stedim Biotech (FR:DIM)
:DIM
Want to see FR:DIM full AI Analyst Report?
DIM Stock Chart & Stats
€188.70
€3.85(1.94%)
At close: 4:00 PM EST
€188.70
€3.85(1.94%)
Day’s Range― - ―
52-Week Range€155.40 - €224.00
Previous CloseN/A
Volume6.35K
Average Volume (3M)78.09K
Market Cap
€15.80B
Enterprise Value€17.88B
Total Cash (Recent Filing)€521.20M
Total Debt (Recent Filing)€2.61B
Price to Earnings (P/E)45.9
Beta1.35
Next Earnings
Jul 16, 2026EPS Estimate
1.29Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)1.17
Shares Outstanding97,330,410
10 Day Avg. Volume78,938
30 Day Avg. Volume78,094
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€233.00Price Target Upside23.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)5.09
Revenue Forecast (FY)€3.17B
Bulls Say, Bears Say
Bulls Say
Revenue ReaccelerationA 57% TTM revenue rebound indicates renewed and durable end-market demand for bioprocessing products. Given the company's recurring consumables and systems revenue model, sustained top-line growth supports scale advantages, backlog conversion and continued investment in product and service offerings over the next several quarters.
Solid Operating ProfitabilityMeaningful operating margins (EBIT ~17%, EBITDA ~28%) show the business still generates healthy operating cash before financing. These margins provide capacity to fund R&D, aftermarket services and capital equipment support, reflecting structural product differentiation and pricing power in bioprocessing.
Improving LeverageLeverage reduction to ~0.64 signals balance-sheet repair after a more levered period, improving financial flexibility. Lower relative debt reduces refinancing pressure, enabling the company to better fund capex, maintenance of the installed base, and strategic initiatives without immediate liquidity strain.
Bears Say
Margin CompressionA sustained decline in gross and net margins versus recent peaks implies structural pressure on profitability, reducing cash available for reinvestment and shareholder return. If margins do not recover, long-term ROE and ability to self-fund growth initiatives will remain constrained.
Weak FCF ConversionFree cash flow at about 35% of net income shows limited conversion of accounting profits into discretionary cash. Persistent weak FCF conversion restricts the firm's capacity to rapidly deleverage, increase dividends, or fund larger organic expansion without relying on external financing.
Modest ROE And Sizeable DebtROE around 6–7% is muted versus historical peaks, indicating lower returns on invested capital. Combined with sizeable absolute debt, the company faces limited capital efficiency and potentially higher financing costs, which could constrain strategic flexibility during prolonged margin cycles.
Sartorius Stedim Biotech News
DIM FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was €155.40 and its highest was €224.00 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €15.80B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Jul 16, 2026 which is in 81 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Apr 23, 2026. The company reported €1.17 earnings per share for the quarter, missing the consensus estimate of €1.211 by -€0.041.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays a Notavailable dividend of €0.69 which represents an annual dividend yield of 0.31%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.29.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.17 in its last earnings report, missing expectations of €1.211. Following the earnings report the stock price went down -14.185%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in FR:DIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
DIM Stock 12 Month Forecast
Average Price Target
€233.00
▲(23.48% Upside)
Technical Analysis
Options Prices
Currently, No data available
---